Breast cancer Drug-induced cardiomyopathy
Conditions
Interventions
None listed
Sponsors
Tohoku University
Hokkaido University Hospital Dokkyo Medical University Hospital Nihon University Graduate School of Medicine St.Luke'
s International Hospital Sapporo Medical University Hospital Osaki Citizen Hospital Kesen-numa City Hospital Saka Hospital Tohoku Medical and Pharmaceutical University Hospital Tohoku University Hospital Tohoku Kosai Hospital Miyagi Cancer Center Fukushima Medical University Juntendo University Hospital Showa University Hospital Kitasato University Hospital St. Marianna University School of Medicine Kanazawa University Hospital Mie University Hospital Kyoto University Hospital O
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients who will receive chemotherapy in medical institutions for clinical trials. (2)Informed consent in writing.
Exclusion criteria
Exclusion criteria: (1)Patients who are judged irrelevant to this clinical trial by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cardiotoxicity after the treatment for breast cancer(a drop in LVEF of > 10% from baseline and < 53%) | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of symptomatic heart failure or any other cardiac event after the treatment for breast cancer | — |
Countries
Japan
Contacts
Public ContactKoichiro Sugimura
Tohoku University Department of Cardiovascular Medicine
Outcome results
None listed